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The heart is a dynamic organ that is made up of multiple cell types including muscle 
and non-muscle.  In general the heart is capable of changing due to many factors 
including development, physiological response, and pathological conditions.  
Fibrotic (scarring) and hypertrophic (increase in cell size) diseases of the heart are 
often associated with messengers (such as calcium (Ca2+)) and pathways that 
activate proteins normally expressed only in the developing heart.  One of these 
proteins, vascular smooth muscle alpha actin (SMA), is the predominant actin in 
smooth muscle, but is not normally expressed in the adult heart.  However, SMA is 
activated in response to heart transplant and the associated rejection process (fetal 
reactivation).  The focus of this project is to determine the role of Ca2+ in the 
regulation of SMA in resident non-muscle cell types of the heart. 
    By using cultured cells we have determined that Ca2+ levels and/or Ca2+ agonists 
effect previously identified transcription factors that bind to the SMA promoter.  In 
addition, regulation of at least one of these transcription factors, YB-1, in non-
muscle cells may be controlled by its relative concentration within the nucleus and 
cytoplasm.  A better understanding of the transcriptional factors regulated by Ca2+ 
and those associated with fetal gene reactivation will give a better understanding of 




Tissue fibrosis is the hallmark of many human diseases. In general, it is associated with 
the altered structure and compromised function of many organs damaged by a wide range 
of injuries or agents including infection, autoimmune processes, chemical insults, etc. 
While many of the causes remain unknown, fibrotic diseases are characterized by non-
cellular material (scar tissue) accumulating in affected organs. In the transplanted heart, it 
often precedes hypertrophy (cell growth), another indicator of compromised function, 
which can lead to overload and eventual failure.  One important cell type critically 
important in fibrotic tissue remodeling and scar formation is the myofibroblast. 
   Myofibroblasts are derived from tissue fibroblasts that are “activated” when they 
acquire the ability to express muscle (myo-) proteins involved in both contraction and 
cellular migration.  Myofibroblasts have been shown to provide the contractile function 
necessary for closing open wounds and may play a similar role in reorganizing damaged 
tissue (Also see Cogan, et al., 2002; Subramanian et al., 2002).  For many years, our lab 
has been studying the genetic mechanisms responsible for myofibroblast activation.  One 
of the key components is transforming growth factor-ß (TGF-ß), a pleiotropic cytokine 
involved in both immune suppression and alterations in cellular growth and 
differentiation.  We have demonstrated that TGF-ß activates the smooth muscle actin 
(SMA) gene, an indicator of fibrosis that is also reactivated in cardiac myocytes during 
rejection.  SMA “reactivation” is thought to occur through two distinct pathways.  The 
first pathway affects transcription by causing TGF-ß responsive Smad proteins to 
translocate to the cell nucleus (Also see Massague, et al., 2000).  The second pathway 
involves activation of a protein called Erk, which affects transcription through the 
transcription factor EGR-1.  
   We have attempted here to decipher the potential role that calcium plays in the 
regulation of SMA by TGF-ß in fibroblasts, particularly in regard to the two pathways 
mentioned above.  Because increases in intracellular calcium have been shown to be a 
factor in cardiomyocyte hypertrophy (Wilkins, et al., 2002), we have also attempted to 
understand whether the link between fibrosis and hypertrophy in the heart is related to 
alterations in cellular calcium.  More specifically, the focus of this thesis is to identify 
factors associated with SMA transcription, whose interplay may be affected by calcium 
levels.  It is our hope that after understanding the mechanisms that regulate this important 
indicator gene, we may begin to develop methods that may be useful in the treatment of 
many types of heart diseases. 
 
Materials and Methods 
Cell Culture Methods – Mouse AKR-2B embryonic fibroblasts were maintained in 
McCoy’s 5A medium (Cambrex Bio Science Walkersville, Walkersville, MD) 
supplemented with 5% heat-inactivated fetal bovine serum (hiFBS) and penicillin-
streptomycin (Invitrogen, Carlsbad, CA).  Nonhuman primate Cos7 kidney fibroblasts 
were maintained in DMEM (4.5 g/l D-glucose) supplemented with penicillin-
streptomycin and 10% hiFBS.  All cell lines were grown in a humidified incubator at 
37ºC with 5% CO2.  Fibroblasts were rendered quiescent by a 24-hr exposure to HEPES-
buffered DMEM (1.0 g/l D-glucose) containing 0.5% hiFBS, and penicillin-streptomycin-
Fungizone.  Ionomycin (1μg/ml, final concentration), a calcium ionophore, was added to 
select cultures as a pretreatment for 4hrs.  Recombinant human TGF-ß1 (5 ng/ml final 
concentration; R&D Systems, Minneapolis, MN) was then added to cultures for 6hrs.  
After treatment, RNA or protein extracts were collected for measurements. (Also see 
Subramanian et al., 2004) 
Preparation of cDNA and Real Time PCR Measurements 
RNA was extracted from the cells using TRIzol reagent (1ml) and chloroform (200 μl).  
After vortexing the mixture and centrifuging for 15 min at 14,000 rpm, the upper aqueous 
layer was collected.  Equal volume of isopropanol was added to precipitate RNA and 
collected by centrifuging for 10 min at 14,000 rpm.  The RNA pellet was then washed 
with 75% ethanol, centrifuged for 10 min at 14,000 rpm, and dissolved in 30 μl DEPC-
treated water.  The RNA concentration was determined by a spectrophotometer and 1 μg 
of RNA was used for each reverse transcription to first-strand complementary 
deoxyribonucleic acid (cDNA).  The cDNA synthesis was performed by combining 1 μg 
of RNA with RNA/primer mixtures and by following the procedure described in 
SuperScriptTM First-Strand Synthesis System for RT-PCR by the manufacturer 
(Invitrogen, Carlsbad, CA).  The cDNA was used in real-time polymerase chain reaction 
(PCR) to measure the amount of mRNA initially present in cells.  Amplification of the 
target cDNA was done by using the TaqMan (Applied Biosystems, Foster City, CA) 
fluorescent probe and by following the procedure given by Applied Biosystems for their 
real-time PCR machine (Applied Biosystems, Foster City, CA). 
Preparation of Protein Extracts 
Cells were washed twice with Dulbecco’s phosphate-buffered saline (PBS), scraped into 
fresh PBS, centrifuged at 3000 rpm, and resuspended in eight packed-cell volumes of 
hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM 
phenylmethylsulfonyl fluoride [PMSF], 0.5 mM dithiothreitol [DTT]).  Cells were 
allowed to swell for 10 min on ice before transfer to a Dounce homogenizer and 
disruption with it.  Nuclei were collected from ruptured cells by centrifuging for 15 min 
at 4000 rpm and suspended in one-half packed pellet volume of ice-cold, low salt buffer 
(20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 0.02 M KCl, 0.2 mM EDTA, 0.2 
mM PMSF, 0.5 mM DTT).  High salt buffer (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 
mM MgCl2, 1.2 M KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT) equal to one-half 
packed pellet volume, was added and the nuclei extracted with gentle rocking for 20 min 
at 4ºC.  Extracted nuclear proteins were collected by centrifuging for 20 min at 14,000 
rpm removing the supernatant, and dialyzing it against 50 volumes of dialysis buffer 
containing 20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM 
PMSF, 0.5 mM DTT.  After dialysis, supernatants were clarified by centrifuging at 
14,500 rpm for 20 min for use in biochemical assays. (Also see Subramanian et al., 2004) 
DNA-binding Assay (DBA) 
Synthetic oligonucleotide probes used during this study correspond to sequences present 
in the mouse SMA 5’-flanking region (Min et al., 1990).  Experiment mixtures 
containing nuclear extract (50 μg of protein) and biotinylated oligonucleotides (100pmol; 
Integrated DNA Technologies, Coralville, IA) were incubated in reaction mixtures 
containing poly(dI-dC), 10 mM Tris, pH 7.5, 50 mM NaCl, 0.5 mM DTT, 0.5 mM 
EDTA, 0.12mM PMSF, 4% glycerol.  Protein:biotin:DNA complexes were captured on 
streptavidin-immobilized paramagnetic particles (Promega, Madison, WI; 0.6 
ml/reaction, 30 min incubation).  After washing four times with buffer containing 25 mM 
Tris-HCl, pH 7.5, 1 mM EDTA, and 100 mM NaCl, bound protein was eluted using 2X 
protein denaturing buffer and analyzed by SDS-PAGE and immunoblotting procedures. 
(Also see Subramanian et al., 2004) 
Mammalian Protein Overexpression Plasmids, Cell Transfection, and Reporter Gene 
Assays 
Fibroblasts at 40-50% confluence were transfected with the SMA promoter:reporter 
fusion plasmid VSMP4 and/or plasmids, encoding various transcriptional regulatory 
proteins by using Mirus (Invitrogen, San Diego, CA) transfection reagent, and by 
following protocol provided by the manufacturer (Also see Cogan et al., 2002).  Plasmids 
encoding human Smad 2/3/4 proteins were kindly provided by Drs. L. Choy and R. 
Derynck (University of California San Francisco, San Francisco, CA).  Plasmids were 
purified using QIAGEN preparative resin and a protocol provided by the manufacturer 
(QIAGEN, Valencia, CA).  Forty-eight hours after transfection, cells were washed with 
PBS and then lysed using chloramphenicol acetyltransferase (CAT) enzyme-linked 
immunosorbent assay (ELISA) lysis buffer (Roche Applied Science, Indianapolis, IN).  
Whole cell extracts were clarified at 14,000 rpm for 10 min at 4ºC and stored at -20ºC 
before assay.  Total protein in extracts was determined by bicinchoninic acid colorimetric 
assay (Pierce Chemical, Rockford, IL).  Equivalent amounts of lysed protein were 
evaluated by immunoblot to verify protein overexpression.  CAT reporter gene activity 
was determined using a commercial ELISA kit (Roche Applied Science).  Reporter gene 
expression was normalized with respect to total cell protein, and transefections were 
routinely performed in triplicate and repeated three to five times.  Data sets were 
subjected to analysis of variance to assess statistical significance set at p < 0.05. (Also see 
Subramanian et al., 2004) 
Immunoblotting 
Proteins (10- μg aliquots) were size fractionated by SDS-PAGE by using 10% 
polyacrylamide gels and then electrophoretically transferred to nitrocellulose membranes 
(Schleicher & Schuell, Keene, NH).  After overnight blocking at 4ºC in Tris-buffered 
saline (TBS; 25 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 3% (wt/vol) nonfat dry 
milk and 0.5% bovine serum albumin, blots were incubated with selected rabbit or goat 
polyclonal antibodies (2 μg/ml) for 90 min at room temperature with gentle rocking.  
Antibodies specific for Sp1, EGR, and Smad proteins were obtained commercially (Santa 
Cruz Biotechnology, Santa Cruz, CA) and two different Pur protein-specific antibodies 
(anti-Purα 291-313 and anti-Purβ 302-324) plus a pan-specific Purα/β (42-69) were 
described previously (Kelm et al., 1999a; Subramanian et al., 2002).  Blots were washed 
four times at room temperature over a 40-min period in TBS containing Tween 20 
(0.05% vol/vol).  Horseradish peroxidase-conjugated, goat anti-rabbit secondary antibody 
(1:1500) or horseradish peroxidase-conjugated donkey anti-goat secondary antibody 
(1:2000) was applied to respective blots for 60 min after which time the blots were 
washed, as described above, and developed for chemiluminescence (ECL; Amersham 






In order to determine the role that 
calcium plays in the regulation of the 
SMA gene in fibroblasts we first tested 
the effect of the calcium ionophore 
ionomycin on the SMA reporter 
plasmid (SMP4) with and without 
TGF-ß, a known inducer of SMA 
transcription.  Fig. 1 shows that 
ionomycin by itself did not affect 
SMP4 activity but it did reduce TGF-ß 
activation by a factor of two.  A t-test 
confirmed a significant difference 
between TGF-ß and TGF-ß with 
ionomycin. (t = 6.2, df = 3, p = 0.05) 
   Given the result, we varied 
concentrations of ionomycin in order to 
determine an experimental optimum 
concentration for future experiments.  
Fig. 2 shows CAT assays using levels 
of 0.1, 1, and 10 μg/ml of ionomycin 
with and without TGF-ß.  Results from 


















Fig 1. AKR cells were transfected with the SMP4 plasmid 
and treated with ionomycin and TGFB.  CAT Elisa 
measured reporter gene activty.  Ionomycin eliminated 
some TGFB activation but it did not effect basal acivity of 

















C     TGFB  0.1 Ion   0.1 IT   1 Ion    1 IT    10 Ion  10 IT
Fig 2. AKR cells were transfected with the SMP4 
plasmid and treated with TGFB and differing 
concentrations of ionomycin. CAT Elisa measured 
reporter gene activty. The optimal ionomycin level to 
use for future experiments is 1 μg/ml since it eliminated 
both basal activity and TGFB activation.
was 1 μg/ml because it eliminated TGF-ß activation and had no outward effects of cell 
structure or viability.  0.1 μg/ml did not significantly affect TGF-ß activation.  At 10 
μg/ml, inhibition of TGF-ß appeared to reach a maximum.  However, a significant effect 
on cell survival and viability was noted (visual observation, not shown).  A t-test 
confirmed a significant difference between TGF-ß and TGF-ß with 1 μg/ml of 
ionomycin. (t = 9.7, df = 3, p = 0.05) 
 
Using the optimal 1 μg/ml ionomycin 
concentration discovered in the 
preceding experiment, a temporal study 
was performed varying the amount of 
time transfected cells were treated with 
the drug prior to or following TGF-ß 
activation.  8 hr and 4 hr pretreatments 
along with 5 min and 4 hr post 
treatments relative to TGF-ß addition 
were performed and reporter gene 
activity was assayed.  Fig. 3 
demonstrates that pretreatment for 8hr and 4hr were similar, because both eliminated 
TGF-ß activation of the SMP4 reporter plasmid.  In contrast, post treatments were shown 
to have little effect on TGF-ß activation. A t-test confirmed a significant difference 



















Control   TGFB     8hr Pre   4hr Pre  5 m post 4hr post
Fig 3.  AKR cells were transfected with the SMP4 
plasmid and treated with ionomycin and TGFB for 
differing times. CAT Elisa measured reporter gene 
activty. The 8 & 4hr pretreatment with ionomycin 
eliminated TGFB activation. Therefore, the 4hr 
pretreatment was selected as optimal time.
0.05)  For this reason, subsequent studies using ionomycin were standardized using 4 hr 
pretreatment with the 1 μg/ml optimized dosage. 
   Because reporter gene studies indicated changes in de vovo transcription from the  
SMA promoter in response to calcium, experiments were performed next to determine if 
the calcium ionophore, ionomycin, affects mRNA levels derived from the native SMA 
gene.  Using pre-determined optimal concentrations and the prescribed pretreatments 
determined above, mRNA levels 
were compared to controls using 
quantitative real-time PCR assays.  
Fig. 4 shows that consistent with 
the results obtained in reporter gene 
assays, pretreatment with 
ionomycin eliminated TGF-ß 
activity, but had no effect on basal 
transcription of SMA.  A t-test 
confirmed a significant difference 
between TGF-ß and TGF-ß with 


















Control                  TGFB              Ion. & TGFB
Fig 4.  AKR cells were treated with ionomycin and TGFB. 
Real-time PCR measured mRNA levels. Pretreatment with 
ionomycin eliminated TGFB induction but did not effect 
basal transcription.
   Inhibition of TGF-ß inducibility by ionomycin may act by affecting transcription 
factors within the cell that regulate 
SMA expression.  In order to 
determine the effect that TGF-ß alone 
or TGF-ß and ionomycinon had on the nuclear level or 
promoter binding level of proteins known to bind the 
SMA promoter (Model 1), DNA binding assays (DBA) 
were performed.  Fig. 5 shows that TGF-ß caused an 
increase in binding of EGR to the SMA promoter, 
while ionomycin eliminated this increase. All other 
transcription factors examined,including Pur alpha and 
SP1 were unchanged by either drug.  This result, 
suggests that cellular calcium levels may affect 
pathways of TGF-ß induction, which result in the 
decreased binding of EGR-1 to the SMA promoter.    
Previous studies in our lab and elsewhere 
indicate that TGF-ß activation can occur through two 
separate pathways.  One of these pathways, the ERK 
pathway can affect the activity of the transcription 
factor EGR-1, shown above to also be regulatable by 
calcium.  The other pathway involves the nuclear 
translocation of Smad proteins and, in our system, is also affected by the single-stranded 
repressor binding proteins Pur alpha/beta and MSY-1 (Subramanian et al., 2004).  To 
examine more closely the stoichiometric 
requirements of these transcription 
factors in our cell culture model, we 
over-expressed Smad proteins (Smad 
2,3,4) at increasing concentrations and 
examined the effects on SMA reporter 
gene activity.  Fig 6 shows that 
increasing amounts of Smad protein 
relative to fixed concentrations of the Pur 
alpha repressor are required for 
overriding SMA repression.  Activation 
of SMA in the presence of Pur alpha was 
shown to be highest when an equimolar 
amounts of Smad DNA and Pur alpha 
DNA was transfected, suggesting a 1:1 
stoichiometric ratio in overriding 
repression.  A t-test confirmed a 
significant difference between Pur alpha 
and Pur alpha with equimolar amounts 
of Smad DNA. (t = 23.8, df = 3, p = 
0.05) 
   Similarly, Fig. 7 shows that the effects 


















   Pur α       Pur α          Pur α        Pur α         Pur α
                  SM 0.5x       SM 1x       SM 2x       SM 4x
Fig 6.  Cos7 cells were transfected with Smad proteins 
and Pur α. CAT Elisa measured reporter gene activty. A 
high enough concentration of Smad proteins are 
present they can overcome Pur α repression, with a 4x 



















Pur β         Pur β         Pur β        Pur β        Pur β
                 SM 0.5x      SM 1x       SM 2x       SM 4x
Fig 7.  Cos7 cells were transfected with Smad proteins 
and Pur β. CAT Elisa measured reporter gene activty. A 
high enough concentration of Smad proteins can over 
come Pur β repression, with a 4x concentration of 
Smads being the best concentration.
levels on Pur ß, another known repressor, and optimal relief of repression was seen at 
stoichiometric ratios of transfected DNA at 1:1 ratios.  A t-test confirmed a significant 
difference between Pur ß and Pur ß with equimolar amounts of Smad DNA. (t = 7.8, df = 
3, p = 0.05)  The results of both experiments indicate the increasing levels of Smad 
proteins may override repressor function, although absolute expression remains lower in 
cells co-transfected with Pur beta.   
   It is possible that activator and repressor functions are competitive, because Fig. 8 
shows that in the absence of 
overexpressed repressors, activation 
increases with increased Smad 
overexpressoin activity.  A t-test 
confirmed a significant difference 
between no Smads and maximum 
Smad levels. (t = 95.7, df = 3, p = 0.05) 
It is also possible that Smad levels 
cause changes in protein-protein 
interactions that affect 
activator/repressor availability in the 






















No SM       SM 0.5x      SM 1x        SM 2x        SM 4x
Fig 8. Differing concentration of Smad proteins were 
transfected into Cos7 cells and used to look for the best 
concentration to cause activation. CAT Elisa measured 
reporter gene activty. The optimal concentration of Smad 
proteins to use for future experiments is the 4x. 
Using the maximum levels of Smads overexpression determined above in Cos7 cells, a 
time point experiment was performed 
to determine the onset of activation 
following transfection.  Fig. 9 
illustrates that after 48 hrs, Smad 
overexpression had the greatest effect 
on activation of the SMA reporter 
gene.  A t-test confirmed a significant 
difference between zero hours and 48 




Western blot assay performed with nuclear extracts from cells transfected for 
corresponding time points showed that Smad proteins also reach peak concentrations in 
the nucleus after 48 hrs following 
transfection, Fig 10. 
Increases in nuclear Smad levels 
after 48 hour transfection were 
not seen to affect the nuclear 
levels of either native Pur alpha 
or Pur beta or of any known transcriptional activators of the SMA gene in transfected 


















0 hrs       2 hrs         6 hrs         24 hrs      48 hrs
Fig 9.  4x Smad proteins were transfected into Cos7 
cells and harvested at differing time points. CAT Elisa 
measured reporter gene activty. After 48 hrs, the Smad
proteins show the greatest activation on SMP4 reporter
plasmid.
protein with a similar repressor function on 
the SMA promoter as Pur alpha and Pur ß 
dropped corresponding to rises in Smad 
nuclear levels.  Fig. 11 shows that increased 
Smad overexpression and its accumulation 
in the nucleus affects YB-1 binding to a 
SMA promoter single-stranded probe as 
well as its nuclear and cytoplasmic levels.  
More specifically, as Smad levels rise in 
transfected nuclei, YB-1, a repressor of 
SMA gene transcription, decreases in 
availablility by presumably leaving the 
nucleus and accumulating in the cytoplasm.   
 
Discussion 
A primary purpose of this study was to identify factors associated with SMA 
transcription, whose interplay may be affected by calcium levels.  In the presence of the 
calcium ionophore, ionomycin, TGF-ß activated transcription of SMA was highly 
reduced or eliminated as measured by both reporter gene analysis and real-time PCR 
assays.  This data suggests that Ca2+ levels within the cell seem to play a role, particularly 
in the TGF-ß inducible regulation of SMA gene.  Previous studies in our lab support this 
finding and suggest that transcriptional mechanisms responsible for basal and inducible 
expression of this important marker gene may rely on distinct sets of pathways and 
transcription factors. (Also see Cogan, et al., 2002) Since expression of SMA is a key 
step in the formation of the myofibroblast phenotype, these findings may also have 
important implications in the wound healing process and in fibrotic diseases of a variety 
of organs. 
    Inhibition of both native SMA mRNA and SMA truncated reporter gene levels suggest 
that ionomycin+ eliminates TGF-ß activation through a cis regulatory element and trans-
acting protein whose activity is modified by calcium.  Two potential candidate proteins, 
Pur α and YB-1 (known as MSY-1 in mouse), both repressors of SMA (Kelm, et al., 
1999b), were unaffected (Fig. 5) by treatment with either TGF-ß alone or TGF-ß and 
ionomycin, in this study.  The only protein whose level and promoter binding activity 
was affected was EGR-1.  EGR-1 binding to the SMA gene was highly inducible by 
TGF-ß but was eliminated in the presence of ionomycin.  EGR-1 has been shown to bind 
to the SMA promoter at a site important for TGF-ß inducibility, a site which also binds to 
the transcription factors SP-1 and Pur alpha (unpublished).  Further studies will be 
required to determine whether the binding of EGR-1 to this critical regulatory element is 
important for TGF-ß induction and whether calcium levels within the cell alter this 
induction through EGR-1. Because the ERK pathway, a protein kinase pathway involved 
in TGF-ß induction, is known to regulated EGR-1, the involvement of calcium in this 
pathway will be an important focus of future studies, 
   Smad proteins are involved in TGF-ß signal transduction from the membrane to the 
nucleus and can act independently from the ERK pathway. In this study, however, we 
detected no effect on nuclear Smad levels by either TGF-ß or ionomycin treatment.  
These results suggest that Ca2+ does not elecit changes in nuclear localization under the 
conditions looked at in this study.  Because nuclear localization of Smad proteins 
following TGF-ß induction is well established and has been shown to be measurable only 
at short time intervals (<2 hours in our previous studies), it is possible that the conditions 
necessary for detecting these changes were inadequate.  Despite the fact that no changes 
in nuclear Smad levels were seen when cells were treated with TGF-ß or TGF-ß and 
ionomycin, our previous studies have indicated that Smads can influence Pur alpha and 
YB-1 action on the SMA promoter.  Results obtained here illustrate that high 
concentrations of Smad proteins transfected and over-expressed in Cos7 cells, reverse the 
effects of Pur alpha and Pur beta repression on SMA transcription.  Smad overexpression 
relieved repression most effectively when transfected at an equimolar ratio to Pur alpha 
and Pur Beta (Smad 4x level).  Consistent with these findings, SMA activity was highest 
in studies where Smad protein levels were maximally expressed and appeared in the 
nucleus.  In addition, an increase in nuclear Smad levels was coincident with decreased 
levels of YB-1 protein (human homologue to MSY-1).  This gradual decrease, 
presumably a result of Smad nuclear localization, was also accompanied by an 
accumulation of YB-1 in the cytoplasm over the same time period (as measured by 
interaction between cytoplasmic extracts and the Pyr-rich ssDNA MSY- binding site 
probe).  Future studies will be aimed at determining how and why the accumulation of 
Smad proteins in the nucleus result in YB-1 shuttling from nucleus to cytoplasm and 
whether this is necessary and or important for Smad-dependent gene activation.  
   In summary, Ca2+ eliminates TGF-ß activation and may affect how certain transcription 
factors, particularly EGR-1, bind to the SMA promoter. The antagonistic effect of 
calcium on TGF-ß activation, will require further study, particularly considering the fact 
that increases in cellular calcium have been linked to hypertropy (Wilkins, et al., 2002).  
One possible model, consistent with our data, is that the calcium flux is necessary for 
controlling the action of the fibrotic cytokine TGF-ß, may lead to hypertrophic growth in 
chronically stimulated cells. In our study, we found no clear evidence that Ca2+ affects 
the TGF-ß responsive Smad proteins or other transcription factors (such as YB-1 or 
MSY-1, Pur alpha, Sp1) previously implicated in TGF-ß activation of SMA.  However, 
alterations in Smad protein levels within the nucleus were shown here to be concamittent 
with YB-1 translocation from nucleus to cytoplasm. This translocation event may 
represent a dynamic process important for regulating inducible expression of the SMA 
gene., and, therefore, may be an important marker for fibrotic disease.  Whether or not 
this process is linked to calcium is unknown and will require further studies. 
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